# Saracatinib difumarate

**Cat. No.:** HY-10234A

**CAS No.:** 893428-72-3

**Molecular Formula:** $C_{35}H_{40}ClN_5O_{13}$

**Molecular Weight:** 774.17

**Target:** Src

**Pathway:** Protein Tyrosine Kinase/RTK

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 83.33 mg/mL (107.64 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.2917 mL | 6.4585 mL | 12.9171 mL |
| 5 mM | 0.2583 mL | 1.2917 mL | 2.5834 mL |
| 10 mM | 0.1292 mL | 0.6459 mL | 1.2917 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. [1].

**$IC_{50}$ & Target**

IC50: 2.7 nM (Src), 30 nM (v-Abl), 66 nM (EGFR), 200 nM (c-Kit)[1]

## CUSTOMER VALIDATION

- Signal Transduct Target Ther. 2023 Feb 17;8(1):66.
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Nat Commun. 2023 Apr 24;14(1):2342.
- Leukemia. 2012 Oct;26(10):2233-44.

- Cancer Res. 2023 Dec 14.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3(3), 248-261.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA